Abstract:ABSTRACTChemokines and their receptors play important roles in normal physiological functions and the pathogeneses of a wide range of human diseases, including the entry of human immunodeficiency virus type 1 (HIV-1). However, the use of natural chemokines to probe receptor biology or to develop therapeutic drugs is limited by their lack of selectivity and the poor understanding of mechanisms in ligand-receptor recognition. We addressed these issues by combining chemical and structural biology in research into molecular recognition and inhibitor design. Specifically, the concepts of chemical biology were used to develop synthetically and modularly modified (SMM) chemokines that are unnatural and yet have properties improved over those of natural chemokines in terms of receptor selectivity, affinity, and the ability to explore receptor functions. This was followed by using structural biology to determine the structural basis for synthetically perturbed ligand-receptor selectivity. As a proof-of-principle for this combined chemical and structural-biology approach, we report a noveld-amino acid-containing SMM-chemokine designed based on the natural chemokine called viral macrophage inflammatory protein II (vMIP-II). The incorporation of unnaturald-amino acids enhanced the affinity of this molecule for CXCR4 but significantly diminished that for CCR5 or CCR2, thus yielding much more selective recognition of CXCR4 than wild-type vMIP-II. Thisd-amino acid-containing chemokine also showed more potent and specific inhibitory activity against HIV-1 entry via CXCR4 than natural chemokines. Furthermore, the high-resolution crystal structure of thisd-amino acid-containing chemokine and a molecular-modeling study of its complex with CXCR4 provided the structure-based mechanism for the selective interaction between the ligand and chemokine receptors and the potent anti-HIV activity ofd-amino acid-containing chemokines.

Isolation and Structure of Antagonists of Chemokine Receptor (CCR5).

Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.

Total Synthesis of Anibamine, a Novel Natural Product As a Chemokine Receptor CCR5 Antagonist.

Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents

The Natural Product CCR5 Antagonist Anibamine and Its Analogs As Anti-Prostate Cancer Agents

Chemokine Receptor Ccr5 Functionally Couples to Inhibitory G Proteins and Undergoes Desensitization

Crystal Structure and Structural Mechanism of a Novel Anti-Human Immunodeficiency Virus Andd-Amino Acid-Containing Chemokine

ChemInform Abstract: Anibamine, a Natural Product CCR5 Antagonist, As a Novel Lead for the Development of Antiprostate Cancer Agents.

A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor Ccr5 Heterodimer: Binding Affinity Versus Functional Activities

Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.

Discovery of Structurally Diverse Natural Product Antagonists of Chemokine Receptor CXCR3

Molecular binding mode of PF-232798, a clinical anti-HIV candidate, at chemokine receptor CCR5

Medicinal chemistry of small molecule CCR5 antagonists for blocking HIV-1 entry: a review of structural evolution.

Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives As a Novel Series of CC-Chemokine Receptor 5 Antagonists.

Design, Synthesis, and Biological Activity of Novel Octahydro-1H-pyrrolo[3,2-c]pyridine Derivatives As C-C Chemokine Receptor Type 5 (CCR5) Antagonists

Selection of CC chemokine receptor 5-binding peptide from a phage display peptide library.

The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents.

Identification of Potential CCR5 Inhibitors Through Pharmacophore-Based Virtual Screening, Molecular Dynamics Simulation and Binding Free Energy Analysis

Advances of CCR5 antagonists: From small molecules to macromolecules

Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex

Computational Studies of the Binding Modes of Ccr1 Antagonists